The impact of plasma zinc status on the severity of prostate cancer disease

e16046 Background: Advanced prostate cancer often leads to the development of BM and as a result SREs. Treatment and management of SREs, as well as the underlying disease, influences the patient’s HRQoL and HRU. We evaluated the impact of SREs on HRQoL (FACT-P) and HRU in patients with BM. Methods: Data were extracted from the Adelphi Prostate Cancer Disease-Specific Programme (DSP), a cross-sectional survey of 150 urologists and oncologists and their prostate cancer patients conducted from March to June 2012 in the US. Each specialist completed comprehensive record forms on 12 of their patients being treated for prostate cancer. Patients were invited to complete a questionnaire, which included the FACT-P HRQoL instrument. Patients were stratified by SRE experience to assess the impact of SRE on patients with BM. SRE was defined as an event of bone radiation, bone surgery, fracture, or spinal cord compression. Results: Data were collected from 1,749 prostate cancer patients, of which 941 were identified with BM; SRE status was recorded in 499 BM patients (Table). HRQoL was significantly lower in patients experiencing SREs, while the rate of consultations and likelihood of being hospitalized was significantly higher. Conclusions: SREs result in a significant economic burden on the healthcare system and negative impact on HRQoL in prostate cancer patients with BM. [Table: see text]

Download Full-text

The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph17197247 ◽

2020 ◽

Vol 17 (19) ◽

pp. 7247

Author(s):

Ying-Erh Chou ◽

Po-Jen Yang ◽

Chia-Yen Lin ◽

Yen-Yu Chen ◽

Whei-Ling Chiang ◽

...

Keyword(s):

Prostate Cancer ◽

Real Time ◽

Cancer Progression ◽

Cancer Susceptibility ◽

Clinical Status ◽

Clinicopathological Characteristics ◽

Gleason Grade ◽

Cancer Disease ◽

T Stage ◽

The Impact

Prostate cancer is one of the major cancers of the genitourinary tract. High-mobility group box 1 (HMGB1) was suggested as a promising therapeutic target for prostate cancer. In this study, we aim to elucidate the associations of HMGB1 single nucleotide polymorphisms (SNPs) with prostate cancer susceptibility and clinicopathological characteristics. The HMGB1 SNPs rs1412125, rs2249825, rs1045411, and rs1360485 in 579 prostate cancer patients and 579 cancer-free controls were analyzed with real-time polymerase chain reactions (real-time PCR). All of the data were evaluated with SAS statistical software. Our results showed that the HMGB1 rs1045411 T allele genotype was significantly associated with advanced pathologic T stage (odds ratio (OR) = 1.433, 95% confidence interval (CI) = 1.021–2.012; p = 0.037) and pathologic N1 stage (OR = 2.091, 95% CI = 1.160–3.767; p = 0.012), and the rs1360485 polymorphic CT + TT genotype was associated with pathologic Gleason grade group (4 + 5) (OR = 1.583, 95% CI = 1.017–2.462; p = 0.041), pathologic T stage (3 + 4) (OR = 1.482, 95% CI = 1.061–2.070; p = 0.021), and pathologic N1 stage (OR = 2.131, 95% CI = 1.178–3.852; p = 0.011) compared with their wild-type carriers. In conclusion, our results revealed that the HMGB1 SNPs were associated with the clinical status of prostate cancer. The HMGB1 SNPs may have the potential to predict prostate cancer disease progression.

Download Full-text

The impact and collateral damage of COVID-19 on prostate MRI and guided biopsy operations: Society of Abdominal Radiology Prostate Cancer Disease-Focused Panel survey analysis

Abdominal Radiology ◽

10.1007/s00261-021-03087-8 ◽

2021 ◽

Author(s):

Devaki Shilpa S. Surasi ◽

Xuemei Wang ◽

Tharakeswara K. Bathala ◽

Hyunsoo Hwang ◽

Sandeep Arora ◽

...

Keyword(s):

Prostate Cancer ◽

Collateral Damage ◽

Panel Survey ◽

Survey Analysis ◽

Cancer Disease ◽

Prostate Mri ◽

Abdominal Radiology ◽

Guided Biopsy ◽

The Impact

Download Full-text

Impact of the COVID-19 pandemic on new starts to oral oncology medications in the US

Journal of Oncology Pharmacy Practice ◽

10.1177/10781552211073778 ◽

2022 ◽

pp. 107815522110737

Author(s):

Lynn Neilson ◽

Monal Kohli ◽

Kiraat D Munshi ◽

Samuel K Peasah ◽

Rochelle Henderson ◽

...

Keyword(s):

Prostate Cancer ◽

Drug Users ◽

Healthcare Delivery ◽

Cancer Drug ◽

Prescription Data ◽

Cancer Disease ◽

The Us ◽

Oral Oncology ◽

The Impact ◽

Post Period

Introduction The COVID-19 pandemic has had a significant impact on healthcare delivery. Although others have documented the impact on new cancer diagnoses, trends in new starts for oncology drugs are less clear. We examined changes in new users of oral oncology medications in the US following COVID-19 stay-at-home orders in 2020 compared to prior years. Methods We examined prescription data for members enrolled with a national pharmacy benefits manager in the US from January 1-October 31 of 2018, 2019, and/or 2020. This is a retrospective, observational study comparing new users per 100,000 members per month for all oral oncology drugs, and separately for breast, lung, and prostate cancer, leukemia, and melanoma oral drugs. We performed a difference-in-differences analysis for change in new users from pre-period (prior to pandemic-induced disruption, January-March), to post-period (following pandemic-induced disruption, April-October), between 2020 and 2019, and 2020 and 2018. Results New oral oncology drug users per 100,000 members per month declined by an additional 11.3% in the 2020 post-period compared to 2019 ( p = 0.048). New oral breast cancer drug starts declined by an additional 14.0% in the 2020 post-period compared to 2019 ( p = 0.040). Similar but non-significant trends were found between 2020 and 2018. No significant differences were found between post-period monthly new starts of leukemia, melanoma, lung or prostate cancer disease-specific oral medications. Conclusions Long-term implications of delays in cancer treatment initiation are unclear, although there is concern that patient outcomes may be negatively impacted.

Download Full-text

Relationships between plasma zinc and ferritin with nutritional status in thalassemic children

Paediatrica Indonesiana ◽

10.14238/pi46.5.2006.220-4 ◽

2016 ◽

Vol 46 (5) ◽

pp. 220

Author(s):

Luszy Arijanty ◽

Sri Sudaryati Nasar ◽

Bambang Madiyono ◽

Djajadiman Gatot

Keyword(s):

Nutritional Status ◽

Negative Correlation ◽

Ferritin Level ◽

Venous Blood ◽

Zinc Level ◽

The Body ◽

Zinc Status ◽

Plasma Zinc ◽

Cross Sectional ◽

The Impact

Background Repeated blood transfusions in thalassemic chil-dren can lead to iron overload in the body. High ferritin level leadsto low plasma zinc status because of their competitive inhibition.Previous study found that there was a correlation between plasmazinc level and nutritional status.Objective To obtain plasma zinc level, to investigate the correla-tion between plasma zinc and ferritin, and the impact of plasmazinc on nutritional status in children with thallasemia.Methods A cross sectional study was conducted on 67 thalas-semic children. This study was performed at Thalassemia Center,Cipto Mangunkusumo Hospital, Jakarta, from 1 st until 31 st of March2005. The age of the patients ranged from 4 to 18 years, with fer-ritin levels more than 2000 ng/ml during the last 6 months or totaltransfusion more than 5 liters. The subjects were divided into 2groups, i.e. group 1 (4-10 years) and group 2 (>10-18 years). Di-etary intake was assessed by 3 day-dietary recall. The nutritionalstatus were judged by mid upper arm circumference (MUAC) forage and height for age (H/A). Venous blood was obtained to mea-sure plasma zinc and ferritin levels. Statistical analysis was doneby Student’s t-test (2-tailed) and linear regression analysis.Results We found that 42% subjects were well-nourished, 51%were undernourished, and 7% were severely malnourished. All sub-jects had low plasma zinc status 31.9 (SD 16.9) μg/dl. There was aweak negative correlation between plasma zinc and ferritin level (r= -0.282, P=0.021). Lower zinc intake was detected in 65 out of 67subjects.Conclusion All thalassemic children in our hospital had low plasmazinc level. There was a weak negative correlation between plasmazinc level and ferritin level. There was no significant correlationbetween plasma zinc status and nutritional status

Download Full-text